Transcriptional regulation of glucose sensors in pancreatic 棺-cells and liver: an update by 源�誘몄쁺 et al.
Sensors 2010, 10, 5031-5053; doi:10.3390/s100505031 
 
sensors 
ISSN 1424-8220 
www.mdpi.com/journal/sensors 
Review 
Transcriptional Regulation of Glucose Sensors in Pancreatic  
β-Cells and Liver: An Update  
Jin-Sik Bae 1,2, Tae-Hyun Kim 1,2,3, Mi-Young Kim 1,2, Joo-Man Park 1,2,3 and Yong-Ho Ahn 1,2,3,*  
1 Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine,  
Seoul 120-752, Korea; E-Mails: baejinsik@yuhs.ac (J.-S.B.); taehyun@yuhs.ac (T.-H.K.); 
theresakim@yuhs.ac (M.-Y.K.); jjumans@yuhs.ac (J.-M.P.) 
2 Center for Chronic Metabolic Disease Research, Yonsei University College of Medicine,  
Seoul, Korea 
3 Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul,  
Korea 
* Author to whom correspondence should be addressed; E-Mail: yha111@yuhs.ac;  
Tel.: +82-2-2228-1674; Fax: +82-2-312-5041. 
Received: 1 February 2010; in revised form: 7 May 2010 / Accepted: 13 May 2010 /  
Published: 19 May 2010 
 
Abstract: Pancreatic β-cells and the liver play a key role in glucose homeostasis. After a 
meal or in a state of hyperglycemia, glucose is transported into the β-cells or hepatocytes 
where it is metabolized. In the β-cells, glucose is metabolized to increase the ATP:ADP 
ratio, resulting in the secretion of insulin stored in the vesicle. In the hepatocytes, glucose 
is metabolized to CO2, fatty acids or stored as glycogen. In these cells, solute carrier  
family 2 (SLC2A2) and glucokinase play a key role in sensing and uptaking glucose. 
Dysfunction of these proteins results in the hyperglycemia which is one of the 
characteristics of type 2 diabetes mellitus (T2DM). Thus, studies on the molecular 
mechanisms of their transcriptional regulations are important in understanding 
pathogenesis and combating T2DM. In this paper, we will review a recent update on the 
progress of gene regulation of glucose sensors in the liver and β-cells. 
Keywords: glucose sensor; solute carrier family 2 (SLC2A2); glucokinase (GCK); 
transcription; liver; pancreatic β-cell 
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1. Introduction 
 
Glucose is one of the most important molecules that acts as a basic fuel for energy source and a 
substrate for intermediary metabolism as well. Because of its essential role in the metabolism, most 
cells have evolved to have an apparatus to sense and transport extracellular glucose into the cells. The 
glucose sensing in mammalian cells is regulated by both direct and indirect pathways. In the 
postprandial state, temporarily increased glucose has to be disposed of to prevent the cells from  
gluco-toxicity. After meal, glucose in the blood is absorbed near the portal vein, and metabolized in 
the liver and pancreas [1].  
Blood glucose is transported into the liver and β-cells of pancreas through solute carrier family 2 
(SLC2A2, also known as GLUT2) and immediately phosphorylated by glucokinase present in the liver 
(LGCK) or β-cells (βGCK) which acts as a glucose sensor. Glucose-6-phosphate in the hepatocytes 
undergoes glycolysis, glycogenesis, pentose phosphate pathway, or hexosamine biosynthetic pathway 
depending on the metabolic needs. Both SLC2A2 and GCK have high Km values and high capacity and 
thus are able to sense and transport glucose into hepatocytes or β-cells in proportion to the blood 
glucose level [2]. 
In the β-cells, glucose is metabolized and thereby increases intracellular the ATP:ADP ratio which 
causes suppression of ATP-sensitive K+ channel and triggers insulin secretion [3-5]. In addition, the 
gene expression of insulin is stimulated by glucose and is subjected to control at the  
transcriptional level.  
Most of the type 2 diabetes mellitus (T2DM)-associated genes are mainly involved both in β-cell 
function and peripheral insulin sensitivity. Mutations in the GCK gene are associated with maturity 
onset diabetes of the young (MODY), a subtype of diabetes characterized by monogenic autosomal 
dominant transmission, early age of onset (typically less than 25 years of age) and primary defects in 
β-cell function. MODY are also associated with mutations in the genes encoding transcription factors 
like, hepatic nuclear factor 4 alpha (HNF4A), HNF1 homeobox A (HNF1A), pancreatic and duodenal 
homeobox 1 (PDX1), HNF1 homeobox B (HNF1B) and neurogenic differentiation 1  
(NEUROD1) [6-8]. Furthermore, these transcription factors are known to be involved in the regulation 
of tissue-specific expression of SLC2A2 and/or GCK genes [9]. Dysfunctional mutation in SLC2A2 
gene is also found in one patient with T2DM [10].  
The gene expression of SLC2A2 and GCK is affected by metabolic conditions and are also  
tissue-specific. SLC2A2 is primarily expressed in the liver and β-cells [11,12] and its gene expression 
is affected by the blood glucose and insulin [13,14]. In diabetic animal models, SLC2A2 mRNA level 
is increased in the liver [15], whereas it is decreased in β-cells [16,17]. GCK is expressed mainly in the 
mammalian liver and β-cells, with two alternative promoters that govern tissue-specific  
expression [18-21]. The βGCK promoter (upstream promoter) is regulated by glucose, whereas the 
LGCK promoter (downstream promoter) is regulated by insulin and glucagon [21].  
In this review, we will focus on an update on the transcriptional regulation of SLC2A2 and GCK 
genes in the liver and β-cells. Studying the molecular mechanisms in relation to T2DM will help 
understand its pathogenesis and find potential drug targets for the development of therapeutic drugs. 
Sensors 2010, 10              
 
 
5033
2. Transcriptional Regulation of SLC2A2 in the Liver and β-Cells of Pancreas 
 
Since the cloning of the promoter regions of SLC2A2 gene, numerous studies on the transcriptional 
regulation have been performed (for a review see [9]). Unlike those of human or mouse SLC2A2 genes, 
rat Slc2a2 promoter contains three noncoding exons (exons 1A, 1B, and 1C; Figure 1) [22]. As shown, 
several HNFs are involved in transcriptional regulation of SLC2A2 genes. 
Figure 1. Schematics of transcriptional regulatory elements on the SLC2A2 gene promoter.  
 
 
Abbreviations: HNF1A, HNF1 homeobox A; EP300, E1A binding protein p300; FOXA2, forkhead 
box A2 (also known as HNF3B); PDX1, pancreatic and duodenal homeobox 1; SP1, Sp1 
transcription factor; PAX6, paired box 6; MXD1, MAX dimerization protein 1; EGR1, early 
growth response 1; MAFA, v-maf musculoaponeurotic fibrosarcoma oncogene homolog A; 
NEUROD1, neurogenic differentiation 1; PPARA, peroxisome proliferator-activated receptor 
alpha; PPARG, peroxisome proliferator-activated receptor gamma; FOXO1, forkhead box O1; 
RXRA, retinoic X receptor alpha; ONECUT1, one cut homeobox 1 (also known as HNF6); NR4A1, 
nuclear receptor subfamily 4, group A, member 1; SREBF1c, sterol regulatory element binding 
transcription factor 1c; CEBPA, CCAAT/enhancer binding protein (C/EBP) alpha; CEBPB, 
CCAAT/enhancer binding protein (C/EBP) beta; HRE, HNF response element; PPRE, PPAR 
response element; NBRE, nerve growth factor I-B response element; SRE, SREBF response 
element; C/EBPRE, CEBP response element. +1, transcription start site. 
 
 
Sensors 2010, 10              
 
 
5034
HNF1A is an essential transcription factor for the expression of Slc2a2 gene in β-cells. In 
transgenic mice over-expressing a dominant negative form of HNF1A, the expression of Slc2a2 gene 
is decreased in the pancreatic islets. In Hnf1a knockout mice, the expression of Slc2a2 gene was 
decreased in the pancreatic islets, but not affected in the liver [23-25].  
Both HNF1A and forkhead box A2 (FOXA2, also known as HNF3B) are responsible for  
the tissue-specific expression of the human SLC2A2 gene. These factors synergistically increase the 
promoter activity of human SLC2A2 gene in NIH-3T3 cells. Binding of HNF1A and FOXA2  
to +96/+108 and +114/+120 bp region of human SLC2A2 promoter was identified and these binding 
sites were well conserved in the mouse and rat gene [26]. HNF1A and FOXA2 also upregulate Slc2a2 
mRNA in the kidney of diabetic rats [27]. Another HNF1A binding site (+200/+212 bp) was found in 
the promoter of human SLC2A2 gene. A mutation study revealed that the +200/+212 bp site is more 
important than the +96/+108 bp one in HNF1A-induced SLC2A2 gene expression. Moreover, E1A 
binding protein p300 (EP300) potentiates activity of the human SLC2A2 promoter by interacting with 
the transactivation domain of HNF1A [28]. 
In transgenic mice or adenoviral transduction of recombinant Foxa2 (AdFoxa2), Slc2a2 mRNA 
level was decreased in the liver [29, 30], presumably because FOXA2 represses one cut homeobox 1 
(Onecut1, also known as Hnf6) gene expression, which is a positive regulator of Slc2a2 gene in the 
mouse liver [31]. However, mRNA levels of Slc2a2 and Onecut1 were not altered in liver specific 
Foxa2 knockout mice [32]. In addition, Slc2a2 gene expression was not altered in β-cell specific 
Foxa2 knockout mice [33]. These reports suggest that transactivating effect of FOXA2 on Slc2a2 
promoter may be weak or absent in mouse liver and β-cells.  
FOXA3 (also known as HNF3G) is known to act as a positive regulator of the Slc2a2 gene in the 
liver, although upregulation of the gene was not observed in β-cells [34]. HNF4A is also known to 
activate SLC2A2 gene expression in embryonic stem cells [35] and β-cells [36].  
PDX1 plays a key role in the development of pancreas by orchestrating gene regulation in  
β-cells [37] and is known to upregulate Slc2a2 gene expression through TAAT motif in the Slc2a2 
promoter [38]. Slc2a2 gene expression in the β-cell specific Pdx1 knockout [39,40] and Pdx1 
heterozygote mice [41] is dramatically reduced when compared to that of wild type mice.  
Although PDX1 was shown to bind in vitro to the promoter region of β-cell specific genes, 
including Slc2a2 (EMSA data), chromatin immunoprecipitation (ChIP) assays indicated that PDX1 did 
not bind to the promoter of Slc2a2 gene in the β-TC3 cells. These results suggest that selectivity of 
PDX1 may depend on the cell type specific chromatin structures and/or the presence of interacting 
proteins [42]. Indeed, PDX1 of which binding to Slc2a2 promoter is reinforced by high-mobility group 
N 3 (HMGN3), a chromatin binding protein that is highly expressed in β-cells [43].  
Since various transcription factors, like HNF1A, FOXA2, Sp1 transcription factor (SP1) [44], 
paired box 6 (PAX6) [45], MAX dimerization protein 1 (MXD1) [46], early growth response-1 
(EGR1) [47,48], v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA) [49], 
neurogenic differentiation 1 (NEUROD1) [50], peroxisome proliferator–activated receptor alpha 
(PPARA) [51] and peroxisome proliferator–activated receptor gamma (PPARG) [52], were known to 
be positive-regulators of PDX1 gene, it was speculated that many of these transcription factors may 
indirectly affect gene expression of SLC2A2 through PDX1. Slc2a2 mRNA level was decreased in 
INS832/13 cells in which forkhead transcription factor FOXO1 is overexpressed [53]. Since FOXO1 
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binds to the PDX1 promoter and inhibits FOXA2-induced PDX1 expression, the effect of  
FOXO1-suppression of Slc2a2 gene expression might occur in an indirect way [54].  
V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) is a critical transcription 
factor for β-cell differentiation, although its expression was not observed in adult pancreas  
β-cells [55-57]. Slc2a2 and Pdx1 gene expression is reduced in the embryonic pancreas of Mafb 
knockout mice and MAFB binds to the promoter of Slc2a2 gene in vivo [57]. Because PDX1 is a 
positive regulator of Slc2a2 gene expression, Slc2a2 gene expression may be regulated by MAFB 
either directly or indirectly. Furthermore, Slc2a2 expression is decreased in Mafa-deficient mice [58]. 
However, MAF response element(s) in the Slc2a2 promoter has not been identified.  
PPARG directly activates SLC2A2 gene expression in the liver and β-cells [59-61]. Rosiglitazone 
increased SLC2A2 mRNA level in the primary cultured hepatocytes, Alexander [59] and INS-1  
cells [62]. Troglitazone also increased Slc2a2 mRNA level in primary cultured islets from rats [52,60]. 
In addition, decreased Slc2a2 gene expression in the islets of db/db mouse was restored by 
pioglitazone treatment [63, 64]. RNAi-suppression of Pparg in INS-1 cells caused reduction in Slc2a2 
mRNA levels [52]. The functional PPAR response elements (PPREs) have been identified in the 
promoters of rat [60] and mouse [59] Slc2a2 gene. Therefore, thiazolidinediones (TZDs) may 
contribute to the transport glucose into the liver or β-cell by upregulating SLC2A2 gene [61]. PPARA 
also upregulates the Slc2a2 gene expression in the β-cells [51,65]. Ppara null mice showed low level 
of Slc2a2 mRNA in the pancreas [66].  
Glucose increased the Slc2a2 gene expression in the liver and β-cells, both in vivo and  
in vitro [14,67-70]. Recently, we have identified a sterol regulatory element binding transcription 
factor 1 (SREBF1) response element (SRE) in the promoter of mouse Slc2a2 gene, which is responsive 
to glucose in primary cultured hepatocytes [69]. Furthermore, glucose-induction of the Slc2a2 gene 
expression in pancreatic islets was not found in Srebf1 knockout mice [70].  
Also, cyclic adenosine monophosphate (cAMP) prevents the glucose-mediated stimulation of 
Slc2a2 gene expression in hepatocytes. The –312/+49 bp region of the mouse Slc2a2 promoter is 
responsible for cAMP responsiveness [71]. However, functional cAMP response element(s) within this 
region has not been identified.  
An orphan nuclear receptor NR4A1 (nuclear receptor subfamily 4, group A, member 1) binds to 
nerve growth factor I-B response element (NBRE) in mouse Slc2a2 promoter (–82/–75 bp) and 
increases mRNA level in primary cultured hepatocytes and liver. Furthermore, Slc2a2 mRNA induced 
by NR4A1 is synergistically enhanced by PPARG coactivator 1 alpha (PPARGC1A) [72]. Because 
NR4A1 expression is highly regulated by the cAMP axis in the liver [72], these results are not 
consistent with the previous report that cAMP decreases the promoter activity of the Slc2a2 gene [71]. 
Further studies are needed to elucidate these contradictory results.  
Insulin plays a negative role in Slc2a2 gene expression in the liver [14]. Since insulin-FOXO1 
pathway is responsible for the negative role in insulin-mediated gene expression [73], it is tempting to 
speculate that FOXO1 may be a negative regulator of Slc2a2 gene expression. However, there is no 
evidence that FOXO1 is involved in the gene expression of Slc2a2 in the liver, although its negative 
role of FOXO1 in the Slc2a2 gene expression was shown in β-cells.  
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CCAAT/enhancer binding protein (CEBP) is shown to activate rat Slc2a2 promoter in HepG2 cells. 
The promoter has two CEBP consensus sequences binding CEBPA and CEBPB (Figure 1). These 
factors synergistically activate the promoter [74]. 
Kruppel-like factor 7 (KLF7) is known to reduce mRNA level of SLC2A2 in HIT-T15 and HepG2 
cells. Because KLF7 is shown to reduce PDX1 gene expression in HIT-T15 cells [75], SLC2A2 gene 
expression may be regulated by KLF7 either directly or indirectly.  
Although tissue-specific transcriptional regulation is not absolutely consistent between human and 
mouse [76], SLC2A2 gene expression in liver was activated by ONECUT1, FOXA3, PPARG, 
SREBF1c, NR4A1, CEBPA, CEBPB and KLF7. On the other hand, SLC2A2 gene expression in  
β-cells was activated by HNF1A, HNF4A, PDX1, HMGN3, MAFA, MAFB, PPARA, PPARG and 
KLF7 and was suppressed by FOXO1. The gene expression or activity of these regulators in abnormal 
conditions like high-fat or high-carbohydrate diet and cellular stress may contribute to the etiology  
of T2DM. 
 
3. Transcriptional Regulation of Glucokinase (GCK) 
 
3.1. Beta Cell Glucokinase (βGCK)  
 
GCK plays a critical role in maintaining the postprandial glucose level near 5 mM, which is 
achieved by glucose stimulated insulin secretion (GSIS) from β-cells and glucose metabolism in the 
liver [77]. βGCK is a primary determinant of blood glucose level because it senses glucose for GSIS.  
Upregulation of βGck gene expression by glucose is mediated by insulin. In this mechanism, insulin 
receptor B type, PI3K class 1a and p70 s6 kinase pathway are known to be involved in  
glucose-regulated βGck transcription [78]. Furthermore, βGck gene expression is increased when 
MIN6 cells were cultured at 30 mM glucose [79]. However, βGck mRNA level is not changed in rats 
which are subjected to fasting/refeeding although LGck gene expression is significantly increased [80]. 
Indeed, the 4 kb promoter reporter construct of the βGck gene was not activated either by glucose (30 
mM) or insulin (20 nM) [81]. These studies indicate that the role of glucose or insulin in the activation 
of βGCK may occur by stabilization rather than upregulation of βGck gene expression in insulinoma 
cells [21].  
As shown in Figure 2, the gene expression of βGCK is regulated by various transcription factors. In 
its 5’-flanking region, there are three upstream promoter elements (UPEs) and two Pal motifs. 
Particulary, UPE-3 and Pal motifs are well conserved in the rat, mouse and human genes [19,82,83]. 
The Pal motifs consist of inverted repeats separated by 1 bp (TGGTCACCA). The promoter activity of 
βGck gene was decreased by the introduction of mutation in the Pal motifs. These Pal motifs are 
pivotal determinants for the neural/neuroendocrine cell-specific expression of the Gck  
promoter [82,83]. 
UPEs have AT-rich sequence, which is known to be responsible for PDX1 activation. PDX1 is a 
master regulator for maintaining function and differentiation of β-cell. In the presence of glucose, 
PDX1 is phosphorylated and translocated into nucleus [84-86]. Expression of PDX1 increased the 
reporter activity of βGck promoter in CHO cells. PDX1 binding site is conserved at UPE3 region in 
human βGCK promoter and may play an essential role for β-cell function [87]. However, β-cell 
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specific disruption of Pdx1 did not affect the expression of βGck although Slc2a2 expression was 
down-regulated [39]. The transcriptional role of PDX1 on the βGCK gene is not fully understood.  
A basic helix-loop-helix (bHLH) transcription factor, NEUROD1 is known to bind βGck promoter 
(–221/–216 bp; E-box) with E47 as a heterodimeric partner and transactivates the βGck gene [88]. In 
addition, nuclear receptor subfamily 0, group B, member 2 (NR0B2, also known as SHP) interacts 
with NEUROD1 and represses the transcriptional activity of NEUROD1 by competing with 
coactivator EP300 [89]  
PPARG/RXRA (retinoic X receptor alpha) binds to the promoter of rat βGck gene of which binding 
element (PPRE) is located at +47/+68 bp. In addition, troglitazone increased the endogenous 
expression and enzyme activity of βGCK [24]. Knockdown of Pparg using siRNA resulted in a 
decrease in the mRNA level of Pdx1, Gck,  Slc2a2 and insulin II [52].  
Figure 2. Schematics of transcriptional regulatory elements on the βGCK gene promoter.  
 
 
Abbreviations: PDX1, pancreatic and duodenal homeobox 1; SP1, Sp1 transcription factor; FOXO1, 
forkhead box O1; NEUROD1, neurogenic differentiation 1; E47, an immunoglobulin  
enhancer-binding factor; EP300, E1A binding protein p300; NR0B2, nuclear receptor subfamily 0, 
group B, member 2 (also known as SHP); PPARG, peroxisome proliferator-activated receptor 
gamma; RXRA, retinoic X receptor alpha; UPE, upstream promoter element; FRE, FOXO1 
response element; PPRE, PPAR response element. 
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In addition, insulin-like growth factor 1 (IGF1) is known to induce βGck gene expression by 
phosphorylating FOXO1. FOXO1 response element (FRE) is located at –550/–543 bp of rat βGck 
promoter and FOXO1 binding to FRE is decreased by IGF1 in vitro [90]. 
Although PDX1, NEUROD1 and NK2 homeobox 2 (NKX2-2) bind to the region of –285/–5 bp in 
the mouse βGck promoter, their respective response elements in the βGck promoter have not been 
characterized [91]. Consistent with a role of NKX2-2 on the βGck promoter, Nkx2-2 knockout mice 
revealed a reduction in the βGck mRNA level. In addition, NKX2-2 appeared to play an important role 
for the differentiation of β-cells [92]. 
 
3.2. Liver Glucokinase (LGCK) 
 
The gene expression of LGck is decreased in streptozotocin-induced diabetic rats and restored by 
insulin administration [93]. In addition, LGck gene expression is increased by insulin and decreased by 
the glucagons-cAMP system in primary cultured hepatocytes [94]. Insulin-induction of LGck gene 
expression is shown to be blocked by LY294002 or wortmannin, a PI3K inhibitor [95]. Furthermore, 
LGck gene expression is inhibited by a dominant negative form of insulin receptor substrate 1  
(IRS1) [96]. These studies support that insulin is a principal regulator of LGck gene expression. 
SREBF1c, one of the master regulators of lipogenesis, is dramatically induced by insulin [97,98]. 
Administration of recombinant adenovirus of Srebf1c to streptozotocin-induced diabetic mice restored 
LGck and lipogenic enzymes normalizing blood glucose level despite that insulin is absent [99]. In 
addition, adenoviral expression of dominant negative form of SREBF1c in primary cultured 
hepatocytes decreased insulin-induction of LGck gene, suggesting a direct participation of SREBF1c 
in the LGck gene expression [100]. Furthermore, direct binding site of SREBF1c on rat LGck promoter 
is identified [101]. However, LGck gene expression is still increased by refeeding the Srebf1c 
knockout mice [102]. Moreover, LGck gene expression is not changed even though Srebf1c was 
knockdown by siRNA although fatty acid synthase mRNA level is decreased. These studies suggest 
that SREBF1c is not likely to be a mediator of LGck gene expression [103, 104]. Further studies are 
needed to answer these contradictory results. 
HNF4A is known to be an important transcription factor for glucose and lipid homeostasis [35,105]. 
HNF4A increases the LGCK gene expression and its binding site HRE (HNF response element) is 
identified in human [106] and rat [107]. During the fasting period, LGCK transcription by HNF4A is 
repressed by FOXO1 which acts as a corepressor, whereas the suppression is restored by feeding 
where FOXO1 is phosphorylated and extruded to cytosol by insulin [106].  
Hypoxia inducible factor 1 alpha subunit (HIF1A) also affects promoter activity of rat LGck gene. 
HIF1A binding site is localized at -87/-80 bp region of the promoter. Both insulin [108] and  
hypoxia [21,109,110] upregulate LGck gene expression by increasing HIF1A level and its  
DNA-binding activity. Transactivation by HIF1A was also enhanced by co-expression of HNF4A and 
EP300. Moreover, HIF1A interacts with HNF4A and each of these factors also interacts with EP300. It 
was suggested that synergy and cooperative interactions between HIF1A, HNF4A and EP300 might be 
necessary for insulin-stimulated LGck expression [109].  
Signal transducer and activator of transcription 5B (STAT5B) is known to be regulated by  
insulin [111,112]. STAT5B phosphorylated by insulin is translocated to the nucleus and increases its 
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binding to the cis-acting elements, thereby increasing the transcription of target genes. Activated 
STAT5B by insulin increased LGCK gene expression [113,114]. In humans, the binding site of 
STAT5B is characterized at -1368/-1360 bp region, but the mouse STAT5 response element 
(STAT5RE) was unknown. The binding affinity of STAT5B to the human LGCK promoter is also 
increased by insulin and the activation by insulin occurs in a janus kinase (JAK)-independent manner. 
Thus, it is suggested that STAT5B plays an important role in the insulin-mediated upregulation of 
LGck gene [113]. However, insulin is known to increase the transcription of LGck in primary cultured 
hepatocytes although the tyrosine phosphorylation of STAT5 was not detectable [114].  
Figure 3. Schematics of transcriptional regulatory elements on the LGCK gene promoter.  
 
 
Abbreviations: STAT5B, signal transducer and activator of transcription 5B; HNF4A, hepatic 
nuclear factor 4 alpha; FOXO1, forkhead box O1; ONECUT1, one cut homeobox 1 (also known as 
HNF6); SREBF1c, sterol regulatory element binding transcription factor 1c; LXRA, liver X 
receptor alpha (also known as NR1H3); RXRA, retinoid X receptor alpha; NR0B2, nuclear 
receptor subfamily 0, group B, member 2 (also known as SHP); EP300, E1A binding protein p300; 
PPARG, peroxisome proliferator-activated receptor gamma; USF2, upstream stimulatory factor 2; 
HIF1A, hypoxia induced factor 1 alpha subunit; STAT5RE, STAT5B response element; HRE, 
HNF response element; FRE, FOXO1 response element; SRE, SREBF response element; PPRE, 
PPAR response element; HIFRE, HIF1A response element; LXRE, LXR response element. 
 
During the fasting period, sirtuin 1 (SIRT1), an NAD+-dependent deacetylase, decreases the rat 
LGck gene expression by deacetylating FOXO1, which results in an increase in binding of FOXO1 to 
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FRE (–537/–529 bp) of its promoter. They also observed that resveratrol enhances interaction of 
between FOXO1 and HNF4A, causing a decrease in the binding affinity of HNF4A to the HRE [115].  
Upstream stimulating factor 2 (USF2) is responsible for the regulation of LGck gene expression by 
binding to the P2 element (–89/–81 bp), and thus, the transcription factor may be in part responsible 
for the glucose homeostasis [116].  
TZDs are anti-diabetic drugs improving glucose utilization and insulin sensitivity. Troglitazone is a 
synthetic ligand of PPARG and is shown to upregulate LGck gene expression. The PPRE is located at 
the –116/–104 bp of LGck gene promoter [117]. 
Recently, liver X receptor alpha (LXRA, also known as NR1H3) was shown to upregulate LGck 
gene expression by binding to the LXR response element (LXRE) (–52/–39 bp) in its promoter. In 
addition, LXRA increases LGck gene expression by inducing SREBF1c and increasing transcriptional 
activity of PPARG. Furthermore, NR0B2 induced by LXRA plays a role in the fine-tuning the LGck 
gene expression [118]. Because the binding site of LXRA and HNF4A seems to be overlapped [107], 
detailed studies are needed to elaborate their precise roles of these factors with regard to specific 
metabolic conditions. 
In mice, ONECUT1 binding site in the LGck gene promoter is localized at –7613/–7622 bp  
and –877/–868 bp, suggesting a possible link between Onecut1 deficiency and development of T2DM. 
This study could explain why T2DM occurs in Onecut1 knockout mice [119,120].  
 
4. Effect of Promoter Polymorphisms on SLC2A2 and GCK Transcription 
 
Single nucleotide polymorphisms (SNPs) in the promoter regions can affect the binding of 
transcription factors regulating the transcription of genes. Some significant promoter SNPs of SLC2A2 
and GCK genes were reported in T2DM patients. 
 
4.1. Promoter Polymorphisms in SLC2A2 Gene 
 
Three common SNPs, –149C > A (rs5393), –122T > C (rs5394) and –44G > A (rs5396), in SLC2A2 
promoter were identified in a Danish population. These SNPs were not significantly different in the 
genotype frequency between T2DM patients and control subjects. In addition, clinical characteristics 
of T2DM were not significantly associated [121]. However, SNPs rs5393 and rs5394 of SLC2A2 could 
be  high risk genotypes to predict the conversion of T2DM in an obese Finnish subject who had 
impaired glucose tolerance [122]. This discrepancy is not explained at present, but it may be due to 
differences in the ethnic group or study population. Detailed functional studies of the effects of 
promoter SNPs on SLC2A2 transcription are needed.  
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4.2. Promoter Polymorphisms in GCK Gene 
 
Recently, a functional βGCK promoter mutation (–71G > C) was identified in Slovakian and British 
patients with GCK-MODY phenotype who have no abnormality of the GCK coding seqeuence. The 
mutation was associated with increased fasting plasma glucose (FPG) levels. In addition, the βGCK 
promoter of the –71C allele showed remarkable reductions of promoter reporter activity in INS-1 cells 
due to the decreased SP1 binding to –82/–67 bp region (Figure 2). These data suggested that the 
mutation was cosegregated with fasting hyperglycemia due to loss of SP1 binding [123]. 
Two SNPs, –6612G > A (rs4607517) [124,125] and –30G > A (rs1799884) [126-129], in the βGCK 
promoter were significantly associated with fasting plasma glucose level in several populations. 
Moreover, the –30G > A SNP has been associated with reduced β-cell function [130], impaired 
glucose tolerance [131] and T2DM [126]. These data suggested that rare alleles of these two SNPs 
may also inhibit the βGCK transcription. However, functional studies of these two SNPs are needed to 
clarify cause-effect in terms of βGCK transcription. 
 
5. Conclusions 
 
Although muscle or adipose tissue have been considered as the principal organs of glucose disposal, 
immediate handling of hyperglycemia in β-cells or liver is also important because high levels of 
glucose are toxic to various tissues. Thus, studies on the regulation of glucose sensors in the liver and 
β-cells are important in understanding T2DM and preventing the long-term complications resulting 
from hyperglycemia. Recent advances in the analytical technologies of genomics and proteomics make 
it possible to unveil the existence of transcription factors and their physical interactions with DNA or 
other coregulators.  
Deeper understanding of the role of transcription factors involved in the gene regulation of the 
glucose sensors in the liver and β-cells may provide important clues in the prevention of the 
occurrence of hyperglycemia-related complications and development of novel therapeutic drugs 
combating T2DM, a world-wide epidemic. 
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